ISSN: 1859 - 2872
Predictors of advanced fibrosis in type 2 diabetic patients with nonalcoholic fatty liver disease
Main Article Content
Keywords
Abstract
Summary
Objective: To identify predictors of advanced fibrosis in patients with nonalcoholic fatty liver disease (NAFLD). Subject and method: This is a cross-sectional study of adult attending Dai Phuoc Ho Chi Minh Polyclinic and the Polyclinic of Pham Ngoc Thach University of Medicine. Liver steatosis and fibrosis was assesed by FibroScan. Nonalcoholic fatty liver disease was diagnosed if CAP > 233dB/m (steatosis > 5%). Data were analyzed using STATA 12 sofware program. Result: A total of 381 type 2 diabetic patients were qualified for study’s criteria. The prevalence of NAFLD in type 2 diabetes mellitus patients based on FibroScan was 72.9%. The prevalence of significant fibrosis (≥ F2), advanced fibrosis (≥ F3) and cirrhosis (F4) were 24.2%, 12.1% and 5.0%, respectively. On multivariate analysis, AST (OR = 1.17, 95% CI: 1.11 - 1.17) and platelet levels (OR = 1.08, 95% CI: 1.02 - 1.19) were independent risk factors of advanced fibrosis in type 2 diabetic patients. Conclusion: Type 2 diabetes mellitus patients had a high prevalence of NAFLD. AST and platelet levels were predicting factors for advanced fibrosis in type 2 diabetic patients.
Keywords: Non-alcoholic fatty liver disease (NAFLD), FibroScan, type 2 diabetes, liver steatosis, liver fibrosis.
Article Details
References
2. Chalasani N, Younossi Z, Lavine J, Charlton M, Cusi K, Rinella M et al (2018) The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the american association for the study of liver diseases. Hepatology 67(1): 328-357.
3. Dyson JK, Anstee QM, McPherson S (2013) Non-alcoholic fatty liver disease: A practical approach to diagnosis and staging. Frontline Gastroenterology: 1-8.
4. EASL, EASD, EASO (2016) EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Journal of Hepatology: 30.
5. Guzelbulut FSM, Akkan-Cetinkaya Z et al (2012) AST-platelet ratio index in the prediction of significant fibrosis and cirrhosis in patients with chronic hepatitis B. Turk J Gastroenterol 23(4): 353-358.
6. Kwok R, Choi K, Wong G, Zhang Y (2015) Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: A prospective cohort study. Gut: 1-10
7. Lai L, Yusoff W, Vethakkan S, Mustapha N (2018) Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography. Journal of Hepatology.
8. Wai CT GJ, Fontana RJ et al (2003) A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 38: 518-526.
9. Younossi Z, Gramlich T, Matteoni C, Boparai N, Mccullough A (2004) Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clinical Gastroenterology and Hepatology 2: 262-265.
10. Younossi Z, Koenig A, Abdelatif D, Fazel Y, Henry L, Wymer M (2016) Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64(1): 73-84
Article Sidebar
